By Cecilia Butini 
 

Roche Holding AG said Monday that its eye treatment Faricimab met its primary endpoint in two phase 3 studies.

The Swiss pharmaceutical major said the studies evaluated the drug--an investigational bispecific antibody--in people with neovascular age-related macular degeneration. They showed that people receiving Faricimab injections at intervals of up to 16 weeks achieved noninferior visual acuity outcomes compared with use of a different drug.

The company said Faricimab was generally well tolerated and didn't present new or unexpected safety signals.

The two studies were Tenaya and Lucerne, Roche said.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

January 25, 2021 01:29 ET (06:29 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.